Biocardia stock.

16 Nov 2023 ... ... $BCDA STOCK ANALYSIS | BIOCARDIA STOCK Related topics : stock analysis stock chart stock news best stock best stocks bcda stock ...SUNNYVALE, Calif., Nov. 16, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA] (the “Company”), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular ...The estimated Net Worth of Peter Altman is at least $849 Tausend dollars as of 28 June 2019. Peter Altman owns over 600 units of BioCardia stock worth over $171,654 and over the last 5 years he sold BCDA stock worth over $0. In addition, he makes $677,501 as President, Chief Executive Officer und Director at BioCardia.Over the past 3 months, 4 analysts have published their opinion on BioCardia (NASDAQ:BCDA) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a ...

Nov 15, 2023 · BioCardia, Inc. price | BioCardia, Inc. Quote Zacks Rank & Other Stocks to Consider. BioCardia currently carries a Zacks Rank #2 (Buy).Some other top-ranked stocks in the overall healthcare sector ...

BioCardia, Inc. is a clinical-stage biotherapeutic company. It engages in the business of developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. The company was founded on January 12, 1994 and is headquartered in Sunnyvale, CA.

SUNNYVALE, Calif., Nov. 16, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA] (the “Company”), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular ...Nov 26, 2023 · Website. n/a. 33. Peter Altman. https://www.biocardia.com. BioCardia, Inc., a clinical-stage regenerative medicine company, engages in development of cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP, an autologous mononuclear cell therapy system for the treatment of ... Related: H.C. Wainwright Sees Over 400% Upside For BioCardia Stock. The therapy incorporates a pre-procedural screening assay to identify patients who may be likely responders, ...BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules. SUNNYVALE, Calif., Nov. 16, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA] (the “Company”), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today …Nov 24, 2023 · According to the issued ratings of 2 analysts in the last year, the consensus rating for BioCardia stock is Moderate Buy based on the current 1 hold rating and 1 buy rating for BCDA. The average twelve-month price prediction for BioCardia is $4.00 with a high price target of $4.00 and a low price target of $4.00.

The estimated Net Worth of Richard M Krasno is at least $297 Thousand dollars as of 17 June 2019. Mr. Krasno owns over 20,000 units of BioCardia stock worth over $27,300 and over the last 17 years he sold BCDA stock worth over $0. In addition, he makes $269,814 as Independent Director at BioCardia.

Convert BioCardia Inc stocks or shares into any currency with our handy tool, and you’ll always know what you’re getting. Select a stock. apple; wise; Select a currency. USD. NASDAQ: BioCardia Inc (BCDAW) = 0.06 USD. Provided by Alpha Vantage. BioCardia Inc stock (BCDAW) in USD. 1 BCDAW = 0.06 USD. 1 month.

8 Nov 2023 ... Stock name: BCDA, Stock Code: BCDA, Company: BioCardia, Inc., Sector: Healthcare.Nov 14, 2023 · BioCardia ( NASDAQ: BCDA) shares jumped over +105% premarket on Tuesday after the biotech firm received FDA approval for the Phase 3 clinical trial of its CardiAMP autologous cell therapy for the ... Mohammed Haneefa Nizamudeen. I first wrote about BioCardia (NASDAQ:BCDA) in June of 2021, explaining why I'd taken a speculative-sized position in the stock.Since then the share price is down (as ...BioCardia ( NASDAQ: BCDA) shares jumped over +105% premarket on Tuesday after the biotech firm received FDA approval for the Phase 3 clinical trial of its CardiAMP autologous cell therapy for the ...Peter Altman became the CEO of BioCardia, Inc. (NASDAQ:BCDA) in 2002, and we think it's a good time to look at the...

SUNNYVALE, Calif., Nov. 16, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA] (the “Company”), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular ...12 Okt 2023 ... What's more, Peter Altman holds US$224k worth of shares in the company in their own name. Component, 2022, 2021, Proportion (2022). Salary, US ...BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules GlobeNewswire 2d Why Beyond Air Shares Are Trading Lower By Around 37%?Most recently, on Friday, May 26th, Peter Altman bought 6,200 shares of BioCardia stock. The stock was acquired at an average cost of $1.60 per share, with a total value of $9,920.00. Following the completion of the transaction, the chief executive officer now directly owns 469,239 shares of the company's stock, valued at $750,782.40.Nov 14, 2023 · BioCardia announces that the Food and Drug Administration (FDA) has approved its proposed CardiAMP Heart Failure II study protocol. The currently ongoing CardiAMP Heart Failure trial has completed enrollment and it is anticipated that the final data analyses will be reported in fourth quarter 2024. BioCardia, Inc. (NASDAQ:BCDA) released its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.21) by $0.05. The business had revenue of $0.82 million for the quarter, compared to analysts' expectations of $0.04 million.Richard has made over 43 trades of the BioCardia stock since 2007, according to the Form 4 filled with the SEC. Most recently he exercised 20,000 units of BCDA stock worth $14,600 on 17 June 2019.

Dec 1, 2023 · Earnings for BioCardia are expected to decrease in the coming year, from ($0.54) to ($0.56) per share. BioCardia has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, April 3rd, 2024 based off prior year's report dates. Read More.

Mr. Fernandez BCDA stock SEC Form 4 insiders trading. Fernando has made over 1 trades of the BioCardia stock since 2018, according to the Form 4 filled with the SEC. Most recently he exercised 14,277 units of BCDA stock worth $5,711 on 13 January 2018.14,277 units of BCDA stock worth $5,711 on 13 January 2018.12 Okt 2023 ... What's more, Peter Altman holds US$224k worth of shares in the company in their own name. Component, 2022, 2021, Proportion (2022). Salary, US ...Nov 29, 2023 · On Tuesday, BioCardia Inc. [NASDAQ:BCDA] saw its stock fall -0.55% to $0.69. On the same session, the stock had its day’s lowest price of $0.60, but rose to a high of $0.6873. Over the last five days, the stock has lost -4.68%. BioCardia Inc. shares have fallen nearly -67.16% since the year began. "Subsidiary" shall have the meaning ascribed to such term in Section 3.1(a). "Trading Day" means a day on which the principal Trading Market is open for trading. "Trading Market" means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq ...BioCardia, Inc. (BCDA) delivered earnings and revenue surprises of -30.77% and 81.18%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?Nov 14, 2023 · BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules GlobeNewswire 14d Why Beyond Air Shares Are Trading Lower By Around 37%? Stock screener. Filter, compare, and track stocks. Commerce des membres de la sociét ... As the Vice President - Operations of BioCardia, the total compensation of Phil Pesta at BioCardia is $276,000. There are 5 …BioCardia Inc. Real-Time Quotes. 0.62. BATS BZX Real-Time Price. As of 12:24pm ET. -0.065 / -9.49%. Today’s Change. 0.36. Today ||| 52-Week Range.SUNNYVALE, Calif., Nov. 16, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA] (the “Company”), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular ...Nov 14, 2023 · Health Topics mentioned in this article. The FDA approved BioCardia Inc's (NASDAQ: BCDA) Phase 3 CardiAMP Heart Failure II study protocol of CardiAMP autologous cell therapy for ischemic heart ...

Biocardia. stock was originally listed at a price of $1,738.17 in Dec 31, 1997. If you had invested in Biocardia stock at $1,738.17, your return over the last 25 years would have been -99.96%, for an annualized return of -27.08% (not including any dividends or dividend reinvestments).

2023 BioCardia Shares Update from Japan PMDA Consultation on CardiAMP Autologous Cell Therapy for Ischemic Heart Failure; Foreign Data Expected to be Sufficient for Product Approval 16 Nov 2023 BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules

Allan Tessler BCDA stock SEC Form 4 insiders trading. Allan has made over 11 trades of the BioCardia stock since 2006, according to the Form 4 filled with the SEC. Most recently Allan bought 400 units of BCDA stock worth $199,200 on 9 March 2020.. The largest trade Allan's ever made was buying 20,000 units of BioCardia stock on 21 …BioCardia Inc. (NASDAQ:BCDA) trade information. BioCardia Inc. (BCDA) registered a 8.23% upside in the last session and has traded in the red over the past 5 sessions. The stock spiked 8.23% in intraday trading to $0.67 this Friday, 12/01/23, hitting a weekly high. The stock’s 5-day price performance is -5.22%, and it has moved by 77.43% in ...16 Nov 2023 ... ... $BCDA STOCK ANALYSIS | BIOCARDIA STOCK Related topics : stock analysis stock chart stock news best stock best stocks bcda stock ...May 30, 2023 · BioCardia has made significant progress in the development of its therapeutic candidates BCDA-01 and BCDA-02. Check out my recommendation on BCDA stock. TipRanks | Stock Market Research, News and Analyst Forecasts - TipRanks.comSep 5, 2023 · The latest update sent BioCardia’s stock down around 20% to 62 cents in premarket trading, adding to losses that have seen the share price slide by more than 60% in six months. BioCardia (NASDAQ:BCDA) and Brainstorm Cell Therapeutics (NASDAQ:BCLI) are both small-cap medical companies, but which is the better investment?We will compare the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, dividends, community ranking, profitability, media sentiment, risk and valuation.BioCardia Inc. () Stock Market info Recommendations: Buy or sell BioCardia stock? Wall Street Stock Market & Finance report, prediction for the future: You'll find the BioCardia share forecasts, stock quote and buy / sell signals below.According to present data BioCardia's BCDA shares and potentially its market environment have been in bearish …Nov 18, 2023 · BioCardia Stock Down 10.0 %. NASDAQ BCDA opened at $0.72 on Tuesday. The stock has a market capitalization of $15.59 million, a P/E ratio of -1.16 and a beta of 1.29. BioCardia has a 52-week low of $0.36 and a 52-week high of $2.92. The firm has a 50-day moving average price of $0.44 and a 200 day moving average price of $1.26. Additional factors that could materially affect actual results can be found in BioCardia’s Form 10-K filed with the Securities and Exchange Commission on March 29, 2023, under the caption titled ...BioCardia Stock Price, News & Analysis (NASDAQ:BCDA) $0.63 -0.05 (-7.35%) (As of 12:50 PM ET) Compare Today's Range $0.62 $0.69 50-Day Range $0.37 …

BIOCARDIA, INC. 2002 STOCK PLAN . STOCK OPTION AGREEMENT . Unless otherwise defined herein, the terms defined in the Plan shall have the same defined meanings in this Option Agreement. I. NOTICE OF STOCK OPTION GRANT . Name: Address: 125 Shoreway Road, Suite B.BioCardia Inc. analyst ratings, historical stock prices, earnings estimates & actuals. BCDA updated stock price target summary.2023 BioCardia Shares Update from Japan PMDA Consultation on CardiAMP Autologous Cell Therapy for Ischemic Heart Failure; Foreign Data Expected to be Sufficient for Product Approval 16 Nov 2023 BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq RulesInstagram:https://instagram. srne tickernon traded reits listemr companynov stocks The gross proceeds to BioCardia, before deducting fees and other offering expenses, are expected to be approximately $3.6 million. The closing of the sale of the securities is expected to occur on ... arkw holdingsis jepi a good long term investment BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules (GlobeNewswire)-15.27%. Nov-15-23 11:04AM BioCardia (BCDA) Soars 168% on FDA Nod to Heart Failure Study (Zacks ... BioCardia, Inc. is a clinical-stage biotherapeutic company. It engages in the business of …BCDA Stock Shows Promising Performance with Potential 863.86% Increase: Analysts Recommend Buying BioCardia Inc. BCDA stock has shown promising performance on November 7, 2023, according to data sourced from CNN Money. The median target price is $4.00, indicating a potential increase of 863.86% from the last recorded price of $0.42. forex auto trading BioCardia Inc. Real-Time Quotes. 0.62. BATS BZX Real-Time Price. As of 12:24pm ET. -0.065 / -9.49%. Today’s Change. 0.36. Today ||| 52-Week Range.BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules. (GlobeNewswire) -15.27%. Nov-15-23 11:04AM. BioCardia (BCDA) Soars 168% on FDA Nod to Heart Failure Study.A high-level overview of BioCardia, Inc. (BCDA) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.